Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trevi TherapeuticsTRVI -3.73%22 PB Ratio is 8.67 as of Aug. 10, 2026. GuruFocus rates TRVI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,223 Biotechnology companies, Trevi Therapeutics ranks worse than 84.55% on this metric.
The historical rank and industry rank for Trevi Therapeutics's PB Ratio or its related term are showing as below:
TRVI'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 9.13
Current: 8.68
During the past 9 years, Trevi Therapeutics's highest PB Ratio was 9.13. The lowest was 0.00. And the median was 0.00.
TRVI's PB Ratio is ranked worse than 84.55% of 1223
companies
in the Biotechnology industry
Industry Median: 2.94
vs TRVI: 8.68
During the past 12 months, Trevi Therapeutics's average Book Value Per Share Growth Rate was 34.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Trevi Therapeutics was 21.10% per year. The lowest was -16.30% per year. And the median was -6.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Trevi Therapeutics PB Ratio Related Terms
Trevi Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Trevi Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Trevi Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trevi Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Trevi Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Trevi Therapeutics (TRVI) has a PB Ratio of 8.67 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Trevi Therapeutics and its competitors. According to the industry distribution chart, Trevi Therapeutics ranks #1034 out of 1223 companies in the Biotechnology industry, placing it in the top 84.5%.
Is Trevi Therapeutics' PB Ratio too high?
Trevi Therapeutics' current PB Ratio is 8.67. The Biotechnology industry median PB Ratio is 2.94. Trevi Therapeutics' value of 8.67 is 194.9% above this industry median. Based on the distribution chart, Trevi Therapeutics ranks #1034 out of 1223 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Trevi Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Trevi Therapeutics' PB Ratio compare to IMNM and VERA?
According to the Biotechnology industry distribution chart, Trevi Therapeutics ranks #1034 out of 1223 companies for PB Ratio. This places Trevi Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.94. Trevi Therapeutics' value of 8.67 is 194.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trevi Therapeutics's current PB Ratio of 8.67 is 194.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Trevi Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trevi Therapeutics's current PB Ratio is 8.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trevi Therapeutics stock overvalued right now?
Trevi Therapeutics (TRVI) has a current PB Ratio of 8.67. The current PB Ratio is 8.67 and 194.9% above the Biotechnology industry median of 2.94. Trevi Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Trevi Therapeutics (TRVI), the current PB Ratio is 8.67 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score
Get the complete analysis for TRVI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRVI has been successfully added to your 
